卡培他滨联合多西紫杉醇对局部晚期乳腺癌患者的临床疗效及免疫功能的影响

The clinical efficacy of capecitabine combined with docetaxel in treatment of patients with locally advanced breast cancer and its influence on immune function

目的 探讨多西紫杉醇联合卡培他滨对局部晚期乳腺癌患者的临床疗效及对免疫功能的影响.方法 选择局部晚期乳腺癌患者160例,按数字表法随机分为观察组及对照组,各80例.对照组给予卡培他滨进行治疗,观察组采用多西紫杉醇联合卡培他滨进行治疗,观察两组临床有效率、中位进展时间、中位生存期、一年生存率以及免疫球蛋白表达水平.结果 观察组临床有效率为88.75%,稳定率为95.00%,均显著高于对照组的68.75%、87.50%,两组差异均有统计学意义（χ^2=5.89、4.17,均P〈0.05）;治疗后,观察组中位进展时间、中位生存期以及一年生存率均显著优于对照组,差异均有统计学意义（t=3.43、5.09、6.23,均P〈0.05）;治疗后,观察组与治疗前相比,IgG、IgM、IgA的表达均有所下降（t=2.34、3.16、3.27,均P〈0.05）,而治疗后对照组与观察组间差异均无统计学意义（t=0.79、0.22、0.27,均P〉0.05）.结论 多西紫杉醇联合卡培他滨治疗局部晚期乳腺癌患者,可提高临床有效率及稳定率,延长患者生存时间,联合使用与采用单药化疗相比对人体免疫功能影响不大,其效果显著优于单独使用卡培他滨,值得在临床上推广使用.

Objective To investigate the efficacy of docetaxel combined with capecitabine in the treatment of patients with locally advanced breast cancer and its effect on immune function.Methods 160 patients with locally advanced breast cancer were randomly divided into observation group and control group.The control group was treated with capecitabine.The patients in the observation group were treated with docetaxel combined with capecitabine.The clinical effective rate, median time to progress, median survival time, one year survival rate and immunoglobulin protein expression levels were observed.Results The clinical effective rate and stable rate in the observation group were 88.75% and 95.00%, which were significantly higher than 68.75% and 87.50% in the control group, the differences were statistically significant （χ^2=5.89,4.17,all P〈0.05）.After treatment, the median time to progression, median survival time and one year survival rate of the observation group were significantly higher than those of the control group （t=3.43,5.09,6.23,all P〈0.05）.Compared with before treatment, after treatment, the IgG,IgM and IgA levels in the observation group significantly decreased（t=2.34,3.16,3.27,all P〈0.05）, while those of the control group were not significantly changed （t=0.79,0.22,0.27,all P〉0.05）.Conclusion Docetaxel combined with capecitabine in the treatment of patients with locally advanced breast cancer can improve the clinical efficacy and stability, prolong the survival time of patients.Compared with using single agent chemotherapy, combined use has no significant effect on human immune function, the effect is better than the use of capecitabine alone, which is worthy of promotion in clinical use.